SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 1995 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ___________ Commission file Number 0-15597 MARSAM PHARMACEUTICALS INC. AND SUBSIDIARY (Exact name of registrant as specified in its charter) DELAWARE 11-2718528 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification Number) Building 31, Olney Avenue, Cherry Hill, New Jersey 08003 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code:(609)424-5600 Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes X No At March 31, 1995 (the close of the Registrant's first fiscal quarter), there were 11,051,562 shares of the Registrant's common stock, par value $. 01 per share (the "Common Stock") outstanding. This 10-Q/A submission is to include a Financial Data Schedule type EX-27 which was inadvertantly omitted in Marsam's prior submission of Form 10-Q. SIGNATURES Pursuant to requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Marsam Pharmaceuticals Inc. (Registrant) Date: July 3, 1995 By: /S/ Marvin Samson Marvin Samson President, Treasurer and Chief Executive Officer Date: July 3, 1995 By: /S/ Richard Baron Richard Baron Vice President, Finance and Chief Financial Officer